Beginning with very low dose (0.2mg) liraglutide in indian type 2 diabetic patients appears better tolerated: experience from real life practice

Majumder Anirban, Bhattacharjee Kingshuk
{"title":"Beginning with very low dose (0.2mg) liraglutide in indian type 2 diabetic patients appears better tolerated: experience from real life practice","authors":"Majumder Anirban, Bhattacharjee Kingshuk","doi":"10.15406/JDMDC.2017.04.00127","DOIUrl":null,"url":null,"abstract":"Submit Manuscript | http://medcraveonline.com Keymessages: Clinicians may start with very low dose (0.2mg per day) liraglutide with subsequent weekly up-titration to minimize the gastrointestinal intolerance of liraglutide therapy, in obese and/or overweight Indian type 2 diabetes patients. Abbreviations: ADA: American Diabetes Association; BMI: Body Mass Index; DBP: Diastolic Blood Pressure; EASD: European Association for the Study of Diabetes; FPG: Fasting Plasma Glucose; GLP-1: Glucagon-Like Peptide-1; GI: Gastrointestinal; Volume 4 Issue 6 2017","PeriodicalId":92240,"journal":{"name":"Journal of diabetes, metabolic disorders & control","volume":"29 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of diabetes, metabolic disorders & control","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/JDMDC.2017.04.00127","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Submit Manuscript | http://medcraveonline.com Keymessages: Clinicians may start with very low dose (0.2mg per day) liraglutide with subsequent weekly up-titration to minimize the gastrointestinal intolerance of liraglutide therapy, in obese and/or overweight Indian type 2 diabetes patients. Abbreviations: ADA: American Diabetes Association; BMI: Body Mass Index; DBP: Diastolic Blood Pressure; EASD: European Association for the Study of Diabetes; FPG: Fasting Plasma Glucose; GLP-1: Glucagon-Like Peptide-1; GI: Gastrointestinal; Volume 4 Issue 6 2017
从印度2型糖尿病患者开始使用极低剂量(0.2mg)利拉鲁肽似乎耐受性更好:来自现实生活实践的经验
关键信息:在肥胖和/或超重的印度2型糖尿病患者中,临床医生可以从非常低剂量(每天0.2mg)利拉鲁肽开始,随后每周增加剂量,以尽量减少利拉鲁肽治疗的胃肠道不耐受。缩写:ADA:美国糖尿病协会;BMI:身体质量指数;DBP:舒张压;欧洲糖尿病研究协会;FPG:空腹血糖;GLP-1:胰高血糖素样肽-1;GI:肠胃;2017年第4卷第6期
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信